128
Views
9
CrossRef citations to date
0
Altmetric
Vaccine Profile

Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers

&
Pages 941-950 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Giulia Piccini, Alessandro Torelli, Elena Gianchecchi, Simona Piccirella & Emanuele Montomoli. (2016) Fighting Neisseria meningitidis: past and current vaccination strategies. Expert Review of Vaccines 15:11, pages 1393-1407.
Read now
Jian-li Hu, Hong Tao, Jing-xin Li, Wei-ming Dai, Bin Song, Jin-fang Sun, Pei Liu, Jie Tang, Wen-yu Liu, Shi-yuan Wang & Feng-cai Zhu. (2015) Safety and immunogenocity of a novel combined Haemophilus influenzae type b–Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old. Human Vaccines & Immunotherapeutics 11:5, pages 1120-1128.
Read now

Articles from other publishers (6)

Sohail Hassan, Iqra Maleeha Nazeer & Abdul Raheem. 2024. Viral Replication Cycle [Working Title]. Viral Replication Cycle [Working Title].
Sarah F. Hale, Lauren Camaione & Ben M. Lomaestro. (2013) MenHibrix. Annals of Pharmacotherapy 48:3, pages 404-411.
Crossref
Charles R. Woods. (2013) Prevention of Meningococcal Infections in the First 2 Years of Life. Pediatric Annals 42:8.
Crossref
Kirsten P. Perrett, Terry M. Nolan & Jodie McVernon. (2013) A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine. Infectious Diseases and Therapy 2:1, pages 1-13.
Crossref
Caroline M. Perry. (2013) Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (HibMenCY-TT; MenHibrix®): A Review. Drugs 73:7, pages 703-713.
Crossref
Thomas A. Russo, Janet M. Beanan, Ruth Olson, Ulrike MacDonald, Andrew D. Cox, Frank St. Michael, Evgeny V. Vinogradov, Brad Spellberg, Nicole R. Luke-Marshall & Anthony A. Campagnari. (2013) The K1 Capsular Polysaccharide from Acinetobacter baumannii Is a Potential Therapeutic Target via Passive Immunization. Infection and Immunity 81:3, pages 915-922.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.